{"protocolSection":{"identificationModule":{"nctId":"NCT01805531","orgStudyIdInfo":{"id":"16398"},"secondaryIdInfos":[{"id":"XA1213FR","type":"OTHER","domain":"Company internal"}],"organization":{"fullName":"Bayer","class":"INDUSTRY"},"briefTitle":"Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication","officialTitle":"Satisfaction and Quality of Life in Patients With a Diagnosis of Non Valvular Atrial Fibrillation Who Take Rivaroxaban for Stroke Prevention","acronym":"SAFARI"},"statusModule":{"statusVerifiedDate":"2017-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-04"},"primaryCompletionDateStruct":{"date":"2015-01","type":"ACTUAL"},"completionDateStruct":{"date":"2015-03","type":"ACTUAL"},"studyFirstSubmitDate":"2013-03-05","studyFirstSubmitQcDate":"2013-03-05","studyFirstPostDateStruct":{"date":"2013-03-06","type":"ESTIMATED"},"lastUpdateSubmitDate":"2017-01-17","lastUpdatePostDateStruct":{"date":"2017-01-18","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bayer","class":"INDUSTRY"},"collaborators":[{"name":"Janssen Scientific Affairs, LLC","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"National, multicenter, prospective, observational, non-interventional study. The objective is to determine if the switch from Vitamin K antagonists (VKA) to Xarelto in subjects treated with VKA with issues for stroke prevention in non valvular atrial fibrillation is associated with an improvement of the treatment satisfaction after 3 months. The treatment satisfaction will be measured by the Anti Clot Treatment Scale (ACTS) score."},"conditionsModule":{"conditions":["Atrial Fibrillation"],"keywords":["SF36 questionnaire","Anti Clot Treatment Scale","Satisfaction","Quality of Life","Rivaroxaban","Stroke prevention"]},"designModule":{"studyType":"OBSERVATIONAL","designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":411,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Rivaroxaban","interventionNames":["Drug: Rivaroxaban (Xarelto, BAY59-7939)"]}],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY59-7939)","description":"20 mg po once daily, which is also the recommended maximum dose. In subjects with moderate creatinine clearance (30-49 ml/min), the dose 15 mg once daily is recommended.","armGroupLabels":["Rivaroxaban"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change of the Anti Clot Treatment Scale (ACTS) score at 3 months compared with baseline score","timeFrame":"After 3 months"}],"secondaryOutcomes":[{"measure":"Change of ACTS score after 1 and 6 months of treatment","timeFrame":"After 1 and 6 months"},{"measure":"Continuation rate at 1, 3 and 6 months","timeFrame":"After 1, 3 and 6 months"},{"measure":"Change of SF36 score at 1, 3 and 6 months (health related quality of life determined by SF36 questionnaire)","timeFrame":"After 1, 3 and 6 months"},{"measure":"Physician's satisfaction at 1, 3 and 6 months assessed by a 5-point Likert scale response (\"very satisfied\", \"satisfied\", \"neutral\", \"unsatisfied\" or \"very unsatisfied\")","timeFrame":"After 1, 3 and 6 months"},{"measure":"Patient's compliance with VKA treatment at baseline and with Xarelto treatment at 1, 3 and 6 months assessed by the investigator as good (≥80%), average (50-80%) or poor (<50%)","timeFrame":"After 1, 3 and 6 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female and male subjects ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation\n* Who are treated with Vitamin K antagonists (VKA) with issues for at least the 4 previous weeks (issues are assessed on medical judgment)\n* Who start treatment with rivaroxaban to prevent stroke or non-CNS (central nervous system) systemic embolism\n* With anticoagulation therapy planned for at least 6 months\n\nExclusion Criteria:\n\n* Contra indication to the use of Xarelto as described in the Summary of Product Characteristics (SmPC); key contra indications are:\n\n  * Hypersensitivity to the active substance or to any of the excipients listed in SmPC section 6.1.\n  * Lesion or condition at significant risk of major bleeding\n  * Concomitant treatment with any other anticoagulant agent\n  * Clinically significant active bleeding\n  * Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C\n  * Pregnancy and breast feeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients more than 18 years old, with a diagnosis of non-valvular atrial fibrillation, treated to prevent stroke or non-central nervous system systemic embolism, who switch from VKA to Xarelto due to issues with VKA","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Bayer Study Director","affiliation":"Bayer","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Many locations","country":"France"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"},{"id":"T6034","name":"Quality of Life","asFound":"Quality of Life","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069552","term":"Rivaroxaban"}],"ancestors":[{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}